Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-rich plasma (PRP) developed by the Royan Institute is an autologous biological therapy investigated for the treatment of knee osteoarthritis. PRP is prepared by concentrating platelets from a patient's own peripheral blood, which, upon activation, release a high concentration of growth factors and bioactive proteins, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). These factors are intended to promote tissue repair, stimulate chondrocyte proliferation, and modulate the inflammatory environment within the osteoarthritic joint. The Royan Institute has conducted Phase 3 clinical trials to evaluate the efficacy of intra-articular PRP injections in reducing pain and improving joint function compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet-rich plasma (Royan Institute).